|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nutrition and physical activity in NAFLD:An overview of the epidemiological evidence显示文摘Nonalcoholic fatty liver disease(NAFLD)has been recognized as a major health burden.The high prevalence of NAFLD is probably due to the contemporary epidemics of obesity,unhealthy dietary pattern,and sedentary lifestyle.The efficacy and safety profile of pharmacotherapy in the treatment of NAFLD remains uncertain and obesity is strongly associated with hepatic steatosis;therefore,the first line of treatment is lifestyle modification.The usual management of NAFLD includes gradual weight reduction and increased physical activity(PA)leading to an improvement in serum liver enzymes,reduced hepatic fatty infiltration,and,in some cases,a reduced degree of hepatic inflammation and fibrosis.Nutrition has been demonstrated to be associated with NAFLD and Non-alcoholic steatohepatitis(NASH)in both animals and humans,and thus serves as a major route of prevention and treatment.However,most human studies are observational and retrospective,allowing limited inference about causal associations.Large prospective studies and clinical trials are now needed to establish a causal relationship.Based on available data,patients should optimally achieve a 5%-10%weight reduction.Setting realistic goals is essential for long-term successful lifestyle modification and more effort must be devoted to informing NAFLD patients of the health benefits of even a modest weight reduction.Furthermore,all NAFLD patients,whether obese or of normal weight,should be informed that a healthy diet has benefits beyond weight reduction.They should be advised to reduce saturated/trans fat and increase polyunsaturated fat,with special emphasize on omega-3 fatty acids.They should reduce added sugar to its minimum,try to avoid soft drinks containing sugar,including fruit juices that contain a lot of fructose,and increase their fiber intake.For the heavy meat eaters,especially those of red and processed meats,less meat and increased fish intake should be recommended.Minimizing fast food intake will also help maintain a healthy diet.PA should be integrated into behavioral therapy in NAFLD,as even small gains in PA and fitness may have significant health benefits.Potentially therapeutic dietary supplements are vitamin E and vitamin D,but both warrant further research.Unbalanced nutrition is not only strongly associated with NAFLD,but is also a risk factor that a large portion of the population is exposed to.Therefore,it is important to identify dietary patterns that will serve as modifiable risk factors for the prevention of NAFLD and its complications. | Shira Zelber-Sagi Ran Oren Zelber-Sagi Vlad Ratziu | 2011 | World Journal of Gastroenterology2011，17，29： | 33 |
| 2 | A position statement on NAFLD/NASH based on the EASL 2009 special conference显示文摘 | Vlad Ratziu Stefano Bellentani Helena Cortez-Pinto Chris Day Giulio Marchesini | 2010 | Journal of Hepatology2010，，2： | 9 |
| 3 | Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification显示文摘AIM:To compare noninvasive methods presently used for steatosis detection and quantification in nonalcoholic fatty liver disease(NAFLD).METHODS:Cross-sectional study of subjects from the general population,a subgroup from the First Israeli National Health Survey,without excessive alcohol consumption or viral hepatitis.All subjects underwent anthropometric measurements and fasting blood tests.Evaluation of liver fat was performed using four noninvasive methods:the SteatoTest;the fatty liver index(FLI);regular abdominal ultrasound(AUS);and the hepatorenal ultrasound index(HRI).Two of the noninvasive methods have been validated vs liver biopsy and were considered as the reference methods:the HRI,the ratio between the median brightness level of the liver and right kidney cortex;and the SteatoTest,a biochemical surrogate marker of liver steatosis.The FLI is calculated by an algorithm based on triglycerides,body mass index,γ-glutamyl-transpeptidase and waist circumference,that has been validated only vs AUS.FLI < 30 rules out and FLI ≥ 60 rules in fatty liver.RESULTS:Three hundred and thirty-eight volunteers met the inclusion and exclusion criteria and had valid tests.The prevalence rate of NAFLD was 31.1% according to AUS.The FLI was very strongly correlated with SteatoTest(r = 0.91,P < 0.001) and to a lesser but significant degree with HRI(r = 0.55,P < 0.001).HRI and SteatoTest were significantly correlated(r = 0.52,P < 0.001).The κ between diagnosis of fatty liver by SteatoTest(≥ S2) and by FLI(≥ 60) was 0.74,which represented good agreement.The sensitivity of FLI vs SteatoTest was 85.5%,specificity 92.6%,positive predictive value(PPV) 74.7%,and negative predictive value(NPV) 96.1%.Most subjects(84.2%) with FLI < 60 had S0 and none had S3-S4.The κ between diagnosis of fatty liver by HRI(≥ 1.5) and by FLI(≥ 60) was 0.43,which represented only moderate agreement.The sensitivity of FLI vs HRI was 56.3%,specificity 86.5%,PPV 57.0%,and NPV 86.1%.The diagnostic accuracy of FLI for steatosis > 5%,as predicted by SteatoTest,yielded an area under the receiver operating characteristic curve(AUROC) of 0.97(95% CI:0.95-0.98).The diagnostic accuracy of FLI for steatosis> 5%,as predicted by HRI,yielded an AUROC of 0.82(95% CI:0.77-0.87).The κ between diagnosis of fatty liver by AUS and by FLI(≥ 60) was 0.48 for the entire sample.However,after exclusion of all subjects with an intermediate FLI score of 30-60,the κ between diagnosis of fatty liver by AUS and by FLI either ≥ 60 or < 30 was 0.65,representing good agreement.Excluding all the subjects with an intermediate FLI score,the sensitivity of FLI was 80.3% and the specificity 87.3%.Only 8.5% of those with FLI < 30 had fatty liver on AUS,but 27.8% of those with FLI ≥ 60 had normal liver on AUS.CONCLUSION:FLI has striking agreement with SteatoTest and moderate agreements with AUS or HRI.However,if intermediate values are excluded FLI has high diagnostic value vs AUS. | Shira Zelber-Sagi Muriel Webb Nimer Assy Laurie Blendis Hanny Yeshua Moshe Leshno Vlad Ratziu Zamir Halpern Ran Oren Erwin Santo | 2013 | World Journal of Gastroenterology2013，19，1： | 8 |
| 4 | Applicability and variability of liver stiffness measurements according to probe position显示文摘AIM: To investigate the liver stiffness measurement (LSM) applicability and variability with reference to three probe positions according to the region of liver biopsy. METHODS: The applicability for LSM was defined as at least 10 valid measurements with a success rate greater than 60% and an interquartile range/median LSM < 30%. The LSM variability compared the inter-position concordance and the concordance with FibroTest. RESULTS: Four hundred and forty two consecutive patients were included. The applicability of the anterior position (81%) was significantly higher than that of the reference (69%) and lower positions (68%), (both P = 0.0001). There was a signif icant difference (0.5 kPa, 95% CI 0.13-0.89; P < 0.0001) between mean LSM estimated at the reference position (9.3 kPa) vs the anterior position (8.8 kPa). Discordance between positions was associated with thoracic fold (P = 0.008). The discordance rate between the reference position result and FibroTest was higher when the 7.1 kPa cutoff was used to define advanced fibrosis instead of 8.8 kPa (33.6% vs 23.5%, P = 0.03).CONCLUSION: The anterior position of the probe should be the fi rst choice for LSM using Fibroscan, as it has a higher applicability without higher variability compared to the usual liver biopsy position. | Patrick Ingiliz Kim Pav Chhay Mona Munteanu Pascal Lebray Yen Ngo Dominique Roulot Yves Benhamou Dominique Thabut Vlad Ratziu Thierry Poynard | 2009 | World Journal of Gastroenterology2009，15，27： | 5 |
| 5 | Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease显示文摘 | Vlad Ratziu Frédéric Charlotte Agnès Heurtier Sophie Gombert Philippe Giral Eric Bruckert André Grimaldi Frédérique Capron Thierry Poynard | 2005 | Gastroenterology2005，，7： | 4 |
| 6 | Prognostic value of liver fibrosis and steatosis biomarkers in type‐2 diabetes and dyslipidaemia显示文摘 | H. Perazzo M. Munteanu Y. Ngo P. Lebray N. Seurat F. Rutka M. Couteau S. Jacqueminet P. Giral D. Monneret F. Imbert‐Bismut V. Ratziu A. Hartemann‐Huertier C. Housset T. Poynard | 2014 | Aliment Pharmacol Ther2014，，9： | 3 |
| 7 | Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease显示文摘 | L. Fedchuk F. Nascimbeni R. Pais F. Charlotte C. Housset V. Ratziu | 2014 | Aliment Pharmacol Ther2014，，10： | 3 |
| 8 | From NAFLD in clinical practice to answers from guidelines显示文摘 | Fabio Nascimbeni Raluca Pais Stefano Bellentani Christopher Paul Day Vlad Ratziu Paola Loria Amedeo Lonardo | 2013 | Journal of Hepatology2013，，： | 3 |
| 9 | A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver显示文摘 | Raluca Pais Fréderic Charlotte Larissa Fedchuk Pierre Bedossa Pascal Lebray Thierry Poynard Vlad Ratziu | 2013 | Journal of Hepatology2013，，： | 2 |
| 10 | Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard显示文摘 | Thierry Poynard Mona Munteanu Elena Luckina Hugo Perazzo Yen Ngo Luca Royer Larysa Fedchuk Florence Sattonnet Raluca Pais Pascal Lebray Marika Rudler Dominique Thabut Vlad Ratziu | 2013 | Journal of Hepatology2013，，5： | 2 |
| 11 | Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study显示文摘 | Jorg Petersen Vlad Ratziu Maria Buti Harry L.A. Janssen Ashley Brown Pietro Lampertico Jan Schollmeyer Fabien Zoulim Heiner Wedemeyer Martina Sterneck Thomas Berg Christoph Sarrazin Marc Lutgehetmann Peter Buggisch | 2011 | Journal of Hepatology2011，，3： | 2 |
| 12 | A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver<!-- Doctopic: GMD -->显示文摘 | Raluca Pais Fréderic Charlotte Larissa Fedchuk Pierre Bedossa Pascal Lebray Thierry Poynard Vlad Ratziu | 2013 | Journal of Hepatology2013，，： | 2 |
| 13 | 非酒精性脂肪肝活组织检查的抽样变异性 | Ratziu V. Charlotte F. Heurtier A. 李宏宇 | 2005 | 世界核心医学期刊文摘(胃肠病学分册)2005，0，10： | 2 |
| 14 | Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest?) and transient elastography (FibroScan?)显示文摘 | Thierry Poynard Julien Vergniol Yen Ngo Juliette Foucher Mona Munteanu Wassil Merrouche Massimo Colombo Vincent Thibault Eugene Schiff Clifford A. Brass Janice K. Albrecht Marika Rudler Olivier Deckmyn Pascal Lebray Dominique Thabut Vlad Ratziu Victor de | 2013 | Journal of Hepatology2013，，： | 2 |
| 15 | Viral hepatitis B显示文摘 | Ching Lung Lai Vlad Ratziu Man-Fung Yuen Thierry Poynard | 2003 | The Lancet2003，，9401： | 2 |
| 16 | Biochemical markers of liver fibrosis in patients with hepatitis C virus infection:a prospective study显示文摘 | Inbert-Bismut F Ratziu V Laurence PL | 2001 | Lancet2001，357，2： | 1 |
| 17 | Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant 显示文摘 | Ratziu V Thibanh V Benhamou Y | 2006 | Comp Hepatol2006，5，： | 1 |
| 18 | Biochemical markers of liver fibrosis in patients with hepatitis C virus infection : a prospective study 显示文摘 | Imbert - Bismut F Ratziu V Pieroni L | 2001 | Lancet2001，357，9262： | 1 |
| 19 | Pharmacologic therapy of non-alcoholic steatohepatitis 显示文摘 | Ratziu V Zelber-Sagi S | 2009 | Clin Liver Dis2009，13，4： | 1 |
| 20 | Viral hepatitis B 显示文摘 | Lai CL Ratziu V Yuen MF | 2003 | Lancet2003，362，9401： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员